Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Pipeline Review, 2019

Lymphocyte activation gene 3 protein is one of the important checkpoints in defense mechanism which is present on the surface of effector T cells and regulatory T cells. These special types of proteins play a prominent role in functioning and controlling of effector and regulatory T cells in order to create an immune response to foreign cells. Lymphocyte Activation Gene 3 (LAG 3) protein is one of the important prognostic indicators of inadequate treatment outcomes of chronic lymphocytic leukemia, moreover, it plays a modulating role in autoimmune diabetes.

Pharmaceutical companies and academic centers & research institutes are prominently focusing on studying and developing new treatment options for the Lymphocyte Activation Gene 3 Protein. For instance; XmAb22841, which is being studied by Xencor, is currently in phase-1 clinical trials to check its efficacy and tolerability for the treatment of gastrointestinal stromal tumors (GIST) and neuroendocrine tumors (NET). However, in preclinical studies, XmAb18087 has shown its potential in the stimulation of target-dependent T-cell activation.

At present around 99% of the pipeline candidates for lymphocyte activation gene 3 protein are in the phase-1 and phase-2 stage. Currently, there is no molecule available in phase 3 and phase 4. Majority of the studies have been sponsored by pharmaceutical companies and research institutes & academic centers.

Report Description

The report on ‘Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3).

The report on ‘Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

• Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary